Jump to content
Wikipedia The Free Encyclopedia

Potrasertib

From Wikipedia, the free encyclopedia
This article is an orphan, as no other articles link to it . Please introduce links to this page from related articles . (December 2024)

Pharmaceutical compound
Potrasertib
Clinical data
Other namesIMP7068
Identifiers
  • 7-(2,6-dichlorophenyl)-12-[3-methyl-4-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]anilino]-2,5,7,11,13-pentazatricyclo[7.4.0.02,6]trideca-1(13),5,9,11-tetraen-8-one
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C28H30Cl2N8O
Molar mass 565.50g·mol−1
3D model (JSmol)
  • C[C@@H]1CN(C[C@@H](N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C
  • InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+
  • Key:BNVDJVMTLDUCGH-HDICACEKSA-N

Potrasertib is an investigational new drug that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is an orally administered inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints.[1] [2]

References

[edit ]
  1. ↑ "IMP 7068". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259 . PMID 38231277.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

AltStyle によって変換されたページ (->オリジナル) /